Digital Therapeutics Podcast with Eugene Borukhovich

Digital Health Today with Eugene Borukhovich

Host Eugene Borukhovich explores how non-molecular therapies and interventions can prevent, manage or even cure diseases. Learn about the rapidly evolving field of Digital Therapeutics, its history, the evolving regulatory and reimbursement frameworks, and the trailblazers creating and advancing this industry.

Trailer: Introducing Digital Therapeutics with Eugene Borukhovich
Trailer 47 sec

All Episodes

In this final episode of Digital Therapeutics Edition, Eugene and his journalistic partner, Brian Dolan, reflect on the lessons learned, guest experts, and inspiring stories featured in season one. Brian is a journalist and the founder and lead writer of Exits & Outcomes, and in each episode, he asked the guests a pointed and challenging question about their digital solutions or their outlook on the DTx industry.  It's been an eventful five months, Brian says -- companies have been bought, merged, and sold, and have raised impressive rounds of funding -- but there are other areas that have seen little progress since the podcast was launched. There may be a season 2 of Digital Therapeutics Edition, but in the meantime, head over to healthxl.com/dtx to continue the conversation with Eugene and other experts. What do you think the future of DTx will look like?  >>Click here to read the transcript Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Jun 1

26 min 8 sec

Abhishek Shah, the CEO and founder of Wellthy Therapeutics, is driven by the challenge of improving care delivery and outcomes for serious or chronic diseases like hypertension, type 2 diabetes, and kidney disease. Abhishek decided to start Wellthy after a successful career as an investor; he was inspired by the incredible ideas of other entrepreneurs, and tired of sitting on the sidelines, decided to build something himself.  Eugene and Abhishek talked back in December, and in that time, Wellthy has laid the groundwork for expansion throughout Asia Pacific and Europe. Eugene and Abhishek talk about his efforts to get investors to back Wellthy, the technology and regulatory landscape for DTx in South Asia, and whether Wellthy is facing competition from other industry players like Apollo during the COVID-19 pandemic. >>Click here to read the transcript Guest Links and Resources: Connect with Abhishek Shah: LinkedIn | Twitter Visit Wellthy Therapeutics: Twitter | LinkedIn | Facebook | Instagram | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

May 25

30 min 19 sec

Edward Kliphuis says his love for investing in digital health comes from his love of "playing with toys" and imagining the possible benefit to health outcomes if "damn cool" solutions are scaled significantly.  M Ventures backs many impressive companies-- like BioLink, Sonde Health, and Akili. In this episode, Ed talks to Eugene about M Ventures' founding philosophy (how to cut delayed feedback cycles, which M Ventures views as the biggest threat to humanity), approach to investing, and discusses some of the drivers of capital injections in the DTx space. Also, Ed offers his insight into what makes for a truly successful DTx company. >>Click here to read the transcript Guest Links and Resources: Connect with Edward Kliphuis: LinkedIn Visit Amadeus Capital Partners: Twitter | LinkedIn | Website Visit M Ventures: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

May 18

31 min 18 sec

Will Gibbs came to Octopus Ventures via a circuitous route - which interestingly, included setting up a rare breed pig farm in his native Essex. He landed in venture capital because he loves to build things - especially large-scale solutions for "taboo" or overlooked medical conditions like substance addiction, menopause, and acne.  Will and Eugene peek underneath the hood of venture capital. They discuss Octopus Ventures' investments in companies like Big Health and Quit Genius, the ins and outs of investing in DTx solutions, whether there is a valuation bubble in the DTx space, and Will offers some advice for startups looking to raise funds. >>Click here to read the transcript Viewing in Apple Podcasts? Visit our website for links to everything below: https://digitalhealthtoday.com/dtx/ Guest Links and Resources: Connect with Will Gibbs: LinkedIn https://linkedin.com/in/willgibbs1/ Visit Octopus Ventures: Twitter | LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

May 11

34 min 59 sec

Ciara Clancy remembers the exact moment she decided to found Beats Medical; it was when she realized her Parkinson’s patient was 20 minutes late for metronome therapy because he was frozen at the door of the hospital, unable to take a single step. The metronome therapy, which helps Parkinson’s patients with their walking and movement, was only available in hospitals and via prescription. So Ciara decided to bring the therapy to them. Beats Medical turns a Parkinson’s patient’s phone into a medical device that gives live, visual feedback to help improve fine motor and gross motor skills, speech, and psychological well-being. Beats’ core technology has also been repurposed and deployed for other central nervous system (CNS) disorders and to help children cope with stress during the COVID-19 pandemic. Eugene and Ciara talk about some exciting recent developments in Beats’ product line, the evolution of their B2C and B2B models, and how Beats’ users have consistently driven the company to create better and more effective interventions. >>Click here to read the transcript Guest Links and Resources: Connect with Ciara Clancy: LinkedIn | Twitter Visit Beats Medical Ltd: Twitter | LinkedIn | YouTube| Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

May 4

28 min 56 sec

As a former IBS sufferer, Elena Mustatea knows all too well that our standard model of healthcare does not adequately treat or support people with chronic conditions—especially digestive conditions. Elena eventually took matters into her own hands and attended a detox retreat in Thailand, which restored her physical and mental well-being and gave her the idea to start Bold Health. Bold Health is clinically validated and science-backed, and relieves the painful, life-disrupting symptoms of chronic digestive conditions through cognitive behavioral therapy and relaxation exercises. This intervention is crucial, because as Elena points out, 75% of the population suffers from GI symptoms in any given week, and 30% of the population has a diagnosable, long-term digestive condition. Digestive and autoimmune conditions are an enormous mental health burden and disproportionately affect women. Eugene and Elena talk about Elena’s journey from consulting and venture capital to digital therapeutics, Bold Health’s recent RCT results, and Elena’s view on how digital therapeutics and pharma could work together in the future. >>Click here to read the transcript Guest Links and Resources: Connect with Elena Mustatea: LinkedIn | Twitter Visit Bold Health: Twitter | LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Apr 27

43 min 17 sec

Jonas Duss came to digital therapeutics from a mechanical and chemical engineering background. He landed at Kaia Health after he and his business partner, David Boutellier, realized they all shared a similar mission; to make proven, effective therapies for debilitating chronic conditions more widely accessible through digital platforms. Kaia Health offers people with musculoskeletal conditions virtual physical therapy sessions, complete with a health coach who helps motivate users to stay on track. In this episode, Jonas tells Eugene about Kaia’s founding, the company’s early decision to expand to the US (despite the different regulatory and payment environment), and his driving motivation to help chronic pain sufferers live longer, higher-quality lives. Also, Jonas mentions a McKinsey report on reimbursement in Germany, in which Kaia’s journey is offered as a brief case study. You can find that report here. >>Click here to read the transcript Guest Links and Resources: Connect with Jonas Duss: LinkedIn | Twitter Visit Kaia Health: Twitter | LinkedIn | Instagram | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Apr 20

30 min 14 sec

During his conscripted service with the German Navy, Christian Dierks learned that if you’re the person in charge of rules and administration, you can bring about a lot of change. He took this lesson with him to law school and in the creation of his own law and healthcare consultancy firm, Dierks+Company. Christian was instrumental in the creation of Germany’s 2019 Digital Health Care Act (known as DVG in Germany), which mandates full reimbursement of any prescribed digital health application. In fact, Christian was involved in setting up the legal framework for digital health applications (DiGA) in Germany—and importantly, he convinced health insurers in Germany not to nickname them DiVA, an acronym which would have carried distinctly less gravitas. Starting with this episode, Eugene says farewell (for now) to DTx trailblazers in the United States, and shifts the focus to leaders in Europe, where Christian and other thought leaders are working to broaden access to digital health solutions. Eugene and Christian recorded this episode in January, and since then, there have been some exciting updates to the status of DVG. Namely, the list of approved digital therapies for reimbursement has grown to 13, and Germany is starting to publish early data on the impact of the measure. >>Click here to read the transcript Guest Links and Resources: Connect with Christian Dierks: LinkedIn | Twitter Visit Dierks+Company: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Apr 13

36 min 2 sec

Chris Wasden came to the digital therapeutics space via a circuitous route through Wall Street, Main Street, and academia. A pro at finding ways to leverage digital solutions in the pharmaceutical industry, he was asked to lead HappifyDTx’s digital therapeutics business after he and his students identified it as the best digital health company in the world. Happify just closed an impressive $73 million funding round and continues to innovate clinically validated tools to treat depression, anxiety, and sleep disorders. In this episode, Chris tells Eugene how Happify’s founders moved from creating video games to digital health tools, and why the team took on the mammoth effort of creating an FDA-quality management system for its platform of products. As a result of their hard work, Chris says Happify is the only DTx company out there that has a legitimate, placebo-controlled RCT. >>Click here to read the transcript Guest Links and Resources: Connect with Chris Wasden: LinkedIn | Twitter Visit Happify Health: Twitter| LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Apr 6

41 min 17 sec

Corey McCann says he always wanted to name a company after a fruit, and when he and his team saw an opportunity to “pair” drugs and software to treat serious disease and improve patient outcomes, the name Pear Therapeutics was born. Of course, the other inspiration for the creation of Pear Therapeutics was Genentech, in that Corey and his team wanted to build something big and capitalize on the hundreds of opportunities they see to modify standards of efficacy with software solutions. Corey, Eugene, and Brian talk about Pear’s early foray into the digital therapeutics space and how Pear’s digital therapies incorporate doctors, nurses, health coaches, and other human counselors. Also, for any entrepreneurs looking to start their own venture, Corey has several pearls of wisdom for you—one of which is to choose your investors and board members very wisely. Finally, Corey offers his predictions about the future of prescription digital therapeutics and the policy solutions needed to make PDTs viable for all patients. >>Click here to read the transcript Guest Links and Resources: Connect with Corey McCann: LinkedIn | Twitter Visit Pear Therapeutics: Twitter| LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Mar 30

33 min 55 sec

Ask Chris Bergstrom what gets him out of bed in the morning, and he says very simply: “scale, scale, scale.” Chris brings a powerful blend of experience in start-ups, large companies, and the life sciences to his role as president of Amalgam Rx, a digital platform that brings providers and life sciences companies together to grow digital health solutions. Chris and Eugene talk about Amalgam’s origins and capabilities, and in response to a question from Brian Dolan about Amalgam’s recent acquisition of Avhana Health, Chris reveals that Amalgam has been lucky enough to start off as a fully self-funded venture. Finally, listen in as Chris and Eugene discuss whether the term “digital therapeutic” has become passé. >>Click here to read the transcript Guest Links and Resources: Connect with Chris Bergstrom: LinkedIn Visit Amalgam Rx: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Mar 23

35 min 40 sec

As an engineer, Melinda Decker could have designed widgets or Styrofoam cups or even gone into winemaking. But her passion for improving patient outcomes led her to digital therapeutics, and eventually to Mymee, a direct-to-consumer platform that helps people with autoimmune disorders manage their symptoms. Mymee recognizes that behavior change is hard, so they combine a user-friendly app and data analytics with health coaching, to help users identify their triggers and make long-lasting lifestyle changes that lessen the severity of their symptoms and improve their overall health. Since its founding in 2017, Mymee has collaborated on two publications and recently closed a funding round of $8.7 million. Join Eugene and Melinda’s conversation about digital therapeutics vs. disease management and the path the Mymee team took to getting their solution off the ground. >>Click here to read the transcript Guest Links and Resources: Connect with Melinda Decker: LinkedIn Visit Mymee: Twitter | LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Mar 16

26 min 19 sec

When Peter Hames struggled with insomnia, he couldn’t get access to any treatment other than sleeping pills. Out of “desperation,” he said, Peter self-administered a cognitive behavioral therapy (CBT) course and within weeks was sleeping like a baby. This experience—and his background in experimental psychology and technology—led him to co-found Big Health, a digital therapeutics (DTx) company whose mission is to “help millions back to good mental health.” With 53 peer-reviewed papers and 13 randomized control trials, Big Health is also one of the only DTx companies in the world with an evidence base of its size, rigor, and quality. Join Eugene and Peter as they talk about the early days of digital therapeutics, Big Health’s unique direct-to-consumer approach in the UK and the US, and its deep-rooted commitment to clinical evidence and supporting science. >>Click here to read the transcript Guest Links and Resources: Connect with Peter Hames: LinkedIn Visit Big Health: Twitter | LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Mar 9

33 min 6 sec

There are two kinds of people in the world, says Brent Vaughan — those who prefer to make incremental changes with a lower likelihood of failure, and those who aspire to fix (seemingly) intractable problems that have stymied others. Brent falls in the latter category. A serial entrepreneur, former venture capitalist, and current CEO of Cognito Therapeutics (a DTx company that specializes in neurodegenerative diseases), Brent is also uniquely positioned to evaluate the future of next generation digital therapeutics. Brent and Eugene talk about the differences between prescription and business-to-consumer DTx, the importance of engaging patients and users early on in the development of novel products, and the exciting potential of translational DTx solutions. Eugene’s podcast partner, Brian Dolan, also pops in with a question. >>Click here to read the transcript Guest Links and Resources: Connect with Brent Vaughan: LinkedIn Visit Cognito Therapeutics: Twitter | LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Mar 2

36 min 13 sec

In this episode, I speak with Ed Cox, who is an Executive Vice President of Strategic Alliances and Global Head of Digital Medicines at EVERSANA. In our conversation, we focus on his journey through Dthera and the many lessons learned.  But before we dive in: Those of you who know Ed, will agree, he is a memorable guy, and therefore I am super surprised I can not even remember where we first met but what I do know is that every time I speak with Ed, I feel like I have known him my whole life.   >>Click here to read the transcript Be sure to check out my previous episode where I spoke with David Klein, CEO and Founder of Click Therapeutics - a company that was started in 2012 as a smoking cessation app and now with a pipeline of DTx therapies and a $500M deal with Boehringer Ingelheim.  Guest Links and Resources: Connect with Edward Cox: LinkedIn Visit EVERSANA : Twitter | LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Feb 23

41 min 1 sec

In the last episode, I had the pleasure of speaking with Eddie Martucci, CEO and Founder of Akili Interactive - the creators of EndeavourRx, which is the first and only prescription treatment delivered through a video game. Imagine that! In this episode, I continue my DTx journey with yet another early trailblazer, David Klein, CEO and co-founder of Click Therapeutics. I first met David at Frontiers Health conference a few years back. He struck me as cool and composed, with a clear vision. Tune in as David shares a little bit of his background and how did he come to starting Click Therapeutics back in the day. >>Click here to read the transcript Guest Links and Resources: Connect with David Klein: LinkedIn Visit Click Therapeutics: Twitter | LinkedIn | Facebook | Instagram | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Feb 16

30 min

On the last episode, I got to know Anand Iyer, Chief Strategy Officer at WellDoc, who was instrumental in getting the Digital Therapeutics Alliance up and running. In this episode, the focus on the early trailblazers of the DTx industry continues with Eddie Martucci. Eddie is the CEO and founder of Akili Interactive, which has taken a super interesting go to market approach. I very briefly met Eddie, at a small event during the JPMorgan conference in San Francisco years ago. Eddie's energy and passion for the product exuded while he was showing a crowd of onlookers an early version of a game that is now an actual digital therapy, EndeavorRx Click here to read the transcript Guest Links and Resources: Connect with Eddie Martucci: Twitter | LinkedIn Visit Akili Interactive Labs Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Feb 9

38 min 20 sec

In this episode, we speak with another one of the early trailblazers of the DTx industry, Anand Iyer, the Chief Strategy Officer of Welldoc. I briefly met Anand at a Health XL event in New York City early in 2019, even though Welldoc has been around since 2008. I'm not even sure how we did not run into each other before, but it was great to connect with Anand for this podcast and get to know him and what drives him, not to mention speak about the early days of Welldoc and DTx industry. Click here to read the transcript Guest Links and Resources: Connect with Anand Iyer: Twitter | LinkedIn Visit Welldoc Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Feb 2

45 min 43 sec

In this episode, we speak with one of the founding members of the Digital Therapeutics Alliance ('DTA'), Pierre Leurent. Pierre is the CEO and founder of Voluntis, which is the first publicly listed DTx company on Euronext in Paris. Pierre co-founded Voluntis in 2001 with the mission to improve patients’ experience with their treatment thanks to digital technologies. Now, 20 years later, they have supported more than 600,000 patients and deployed over 50 programs around the world. Pierre is a Director of the Digital Therapeutics Alliance, of which he served as Chairman, and a member of Advamed’s Digital Health Executive Leadership Group. He previously co-chaired the digital therapeutics task force of the Personal Connected Health Alliance, a member of HIMSS, and chaired the eHealth France Alliance regrouping several leading trade organizations representing digital and life sciences companies in France. Pierre holds a MS from Ecole Centrale Paris. Links and Resources: Connect with Pierre Leurent: Twitter | LinkedIn Visit Voluntis Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Jan 26

43 min 54 sec

In the previous episode in this two-part deep dive inside the Digital Therapeutics Alliance, I spoke to Megan Coder, the Executive Director for the DTA. In this episode, I'm excited to chat with Jessica Shull, European lead for the DTA. I met Jessica and Sitges, Spain near Barcelona at a HIMSS EU Health 2.0 event. Jessica struck me as sharp, composed and super knowledgeable, and of course, a great addition to the DTA. With Jessica's leadership, the DTA expanded its coverage across Europe, LATAM and Australia. Click here to read the transcript Links and Resources: Connect with Jessica Shull: Twitter | LinkedIn Visit the Digital Therapeutics Alliance Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Jan 19

27 min 32 sec

In the previous episode, Brian Dolan and I discussed the definition of digital therapeutics. The term 'digital therapeutics' has been used since about 2012, and in 2017 the Digital Therapeutics Alliance, aka DTA, came on the scene. In this two-part deep dive we go inside the DTA and in this episode, we start with Megan Coder, the Executive Director. I remember meeting the energetic, polished, and absolutely no BS, Megan, at the 2017 Frontiers Health in Berlin - yes, when face-to-face conferences were still a thing. At that conference, the DTA was officially launched. I strongly believe this was a historic moment for the overall industry. Click here to read the transcript Links and Resources: Connect with Megan Coder: Twitter Visit the Digital Therapeutics Alliance Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Jan 12

37 min 57 sec

Eugene kicks off the Digital Therapeutics Podcast with journalist and entrepreneur Brian Dolan. Eugene met Brian way back in the pre-iphone days of 'mobile health' (that was before apps, before 4G, before tablets). In this episode, Brian describes how the need for innovation in tech and health led him to create MobiHealthNews. After selling MobiHealthNews to HIMSS in 2015, and is now is the founder and lead writer of Exits and Outcomes. A self-described 'fanboy' of Exits & Outcomes, Eugene invited Brian to be his sparring partner on this limited podcast series. Tune in as they dive into the past, present and future to uncover the truth about Digital Therapeutics. Click here to read the transcript Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Jan 5

31 min 3 sec

In this episode, I have the pleasure of introducing you to one of the health sectors leading innovators, and probably one of the best known and, dare I say it, most loved, leaders I’ve had the pleasure of knowing in my 20 plus years working in healthcare: Eugene Borukhovich. He’s a serial intra- and entrepreneur, executive, venture builder, speaker & board advisor with a focus in digital health. He’s also the Chairman and Founding Board Member at YourCoach.Health and founder of Initium Impact Ventures.  Prior to YourCoach, Eugene served as Global Head of Digital Health at Bayer. He has also co-founded and sold a doctor rating startup and a consulting company. Eugene recently relocated to Barcelona where he enjoys running, writing, traveling and spending time with his family. Click here to read the transcript Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

E

Jan 5

22 min 25 sec

Join host Eugene Borukhovich as he explores how non-molecular therapies and interventions can prevent, manage or even cure diseases. In this limited series produced with Digital Health Today, learn about the rapidly evolving field of Digital Therapeutics, its history, the evolving regulatory and reimbursement frameworks, and the trailblazers creating and advancing this industry.

Nov 2020

47 sec